TherapeuticsMD (TXMD) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
TherapeuticsMD Announces First Quarter 2019 Financial Results
May 6, 2019 4:05 PM EDTBIJUVA Commercial Launch in April 2019
Completed $300 Million Non-Dilutive Term Loan Financing Facility in April 2019
IMVEXXY® Continues Strong Positive Trends for Prescriptions and Patient Refills
Conference Call Scheduled for 4:30 p.m. ET Today
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company, today announced its commercial and corporate update for the first quarter ended March 31, 2019.
We are pleased with our recent progress on achieving several business objectives, which include the on-time launch of... More
